Laboratory monitoring of new antithrombotic drugs.
This article examines laboratory methods that are used or may be used to monitor newly developed heparins, low-dose vitamin K antagonists, new thrombin inhibitors such as recombinant hirudin, and oligopeptide thrombin inhibitors (some of which it is hoped will be orally active), thromboxane receptor antagonists, glycoprotein IIb-IIIa inhibitors, and ticlopidine-like structures.
Breddin
H K
HK
Division of Angiology, J.W. Goethe University, Frankfurt, Germany.
Radziwon
P
P
Boczkowska-Radziwon
B
B
D001780:Blood Coagulation Tests / Q000379:methods*; D016903:Drug Monitoring; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D007753:Laboratories; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors
D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K; D006493:Heparin